Orexigen(R) Therapeutics Schedules November 4, 2009 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2009

Orexigen(R) Therapeutics Schedules November 4, 2009 Webcast Discussion of
Financial Results for the Third Quarter Ended September 30, 2009

SAN DIEGO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics,
Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of
obesity, will announce its financial results for the third quarter ended
September 30, 2009 on Wednesday, November 4, 2009 after the markets close. The
announcement will be followed by a live webcast and conference call at 5:00
p.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial
results and recent business highlights. The live call may be accessed by phone
by calling (866) 783-2138 (domestic) or (857) 350-1597 (international),
participant code 88599521. The webcast can be accessed live on the investor
relations section of the Orexigen web site at http://www.orexigen.com, and
will be archived for 14 days following the call.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on
developing therapies that offer multiple approaches to treating obesity. The
Company's lead investigational product, Contrave®, has completed the COR Phase
3 clinical development program and is on track for a regulatory submission
with the FDA in the first half of 2010. The Company's second obesity drug
candidate, Empatic(TM), has completed Phase 2 trials. Each product candidate
is designed to act on a specific group of neurons in the central nervous
system with the goal of achieving appetite suppression and sustained weight
loss, through combination therapeutic approaches. Further information about
the Company can be found at http://www.Orexigen.com.

SOURCE Orexigen Therapeutics, Inc.

Graham Cooper, Chief Financial Officer of Orexigen Therapeutics, Inc.,
+1-858-875-8600; or Media, Lori Rosen of WeissComm Partners, +1-212-301-7173,
for Orexigen Therapeutics, Inc.